Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

国药集团
SINOPHARM

國藥控股股份有限公司
SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE THIRD QUARTER OF 2026

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "**Company**") dated 30 October 2026 (the "**Announcement**") in relation to the 2026 third quarterly report of China National Accord Medicines Corporation Ltd. ("**Sinopharm Accord**"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the third quarter of 2026 as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".*

PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Unit: Yuan
Currency: RMB

	Reporting Period (Single Quarter)	Changes in the Reporting Period over the same period of last year	From the beginning of the year to the end of the Reporting Period	Changes from the beginning of the year to the end of the Reporting Period over the same period of last year
Revenue	18,799,734,249.87	2.57%	55,066,090,261.80	-0.11%
Net profit attributable to shareholders of the listed company	346,286,483.92	18.91%	952,490,037.32	-0.48%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	345,902,227.88	23.47%	944,776,371.13	2.36%
Net cash flow arising from operating activities	—	—	-502,888,987.94	-8.60%
Basic earnings per share (Yuan/Share)	0.57	18.75%	1.56	0.00%
Diluted earnings per share (Yuan/Share)	0.57	18.75%	1.56	0.00%
Weighted average return on net assets	1.82%	Increased by 0.23 percentage point	5.03%	Decreased by 0.26 percentage point

	At the end of the Reporting Period	At the end of last year	Changes in the end of the Reporting Period over the end of last year
Total assets	48,903,756,421.35	49,096,270,979.03	-0.39%
Equity attributable to shareholders of listed company	19,219,611,069.00	18,609,963,275.57	3.28%

Notes:

(1) "Reporting Period" refers to the three months ended 30 September 2026.

(2) At the 2025 annual general meeting of Sinopharm Accord held on 21 May 2026, the "2025 Profit Distribution Proposal of Sinopharm Accord" was approved, pursuant to which a cash dividend of RMB6.16 per 10 shares (before tax) would be distributed and 1 bonus share per 10 shares would be issued to all shareholders based on a total share capital of 556,565,077 shares as at the end of 2025, resulting in an issuance of 55,656,507 bonus shares and an increase in total share capital of Sinopharm Accord to 612,221,584 shares. The equity distribution was completed for A shares on 24 June 2026 and for B shares on 26 June 2026. In accordance with the relevant requirements of the "Rules on Information Disclosure and Preparation by Companies Offering Securities to the Public No.9 — Calculation and Disclosure of Return on Net Assets and Earnings Per Share", Sinopharm Accord has recalculated the earnings per share for the comparative period based on the total share capital after the bonus share issuance, and has also recalculated the net assets per share attributable to shareholders of the listed company. The basic earnings per share for the period from January to September 2025 and the period from July to September 2025 were adjusted from RMB1.72 and RMB0.52 to RMB1.56 and RMB0.48, respectively.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

For the period from January to September 2026, Sinopharm Accord achieved a revenue of RMB55.066 billion, representing a year-on-year decrease of 0.11%; operating profit of RMB1.327 billion, representing a year-on-year decrease of 0.47%; total profit of RMB1.317 billion, representing a year-on-year decrease of 0.05%; and net profit attributable to shareholders of the listed company of RMB0.952 billion, representing a year-on-year decrease of 0.48%. The weighted average return on net assets decreased by 0.26 percentage points year-on-year. In the third quarter of 2026, Sinopharm Accord achieved a revenue of RMB18.800 billion, representing a year-on-year increase of 2.57%; and net profit attributable to shareholders of the listed company of RMB0.346 billion, representing a year-on-year increase of 18.91%. The performance of each segment is as follows:

For the period from January to September 2026, the distribution segment achieved a revenue of RMB40.565 billion, representing a year-on-year decrease of 0.07%; and net profit of RMB0.754 billion, representing a year-on-year increase of 4.28%. Despite the continued deepening of industry policies, Sinopharm Accord remained committed to strengthening its core business, actively expanding its market presence and adjusting its business structure. The decline in revenue continued to narrow, while profit growth regained momentum, demonstrating strong operational resilience. The retail segment (namely "Sinopharm Holding Guoda Drugstore Co., Ltd.", hereinafter referred to as "**Guoda Drugstore**") achieved a revenue of RMB15.234 billion, representing a year-on-year increase of 0.05%; and net profit of RMB27 million, representing a year-on-year increase of 105.08%. Guoda Drugstore's sales revenue gradually stabilized. Through continuous optimization of its product mix, strategic adjustment of its store network layout, further strengthening of expense control and enhancement of operational quality, Guoda Drugstore achieved year-on-year growth in net profit during the reporting period.

In 2026, the pharmaceutical industry continued to experience the deepening impact of centralized procurement and other policy measures, with industry competition shifting from scale expansion to competition in quality and efficiency. Sinopharm Accord will maintain its strategic focus, proactively adapt to changes in the industry landscape, and continue to enhance supply chain efficiency through lean operations. By actively expanding incremental markets and optimizing its product mix to cultivate new

growth drivers, Sinopharm Accord will continue to break through development bottlenecks and steadily improve its operational quality and profitability.

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
30 October 2026

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.